Sagimet Biosciences Inc. (SGMT) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Sagimet Biosciences reported revenue of $0. Net income was -$51.0M, or -$1.58 per diluted share. Operating activities generated -$45.6M of cash. At fiscal year end, Sagimet Biosciences held $116.5M in total assets against $5.1M in total liabilities, including $35.0M of cash and equivalents.
Open the full interactive Sagimet Biosciences financials → Quarterly statements, key ratios, valuation history and price charts.
Sagimet Biosciences Key Stats
| Share Price | $7.98 |
|---|---|
| Market Cap | $423.9M |
| 52-Week Range | $4.55 – $11.17 |
| Shares Outstanding | 53.1 million (basic, 2026 Q2) |
Sagimet Biosciences Income Statement
| FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|
| Revenue | $2.0M | $0 | $0 |
| Operating Income | -$30.7M | -$54.5M | -$56.9M |
| Pre-Tax Income | -$27.9M | -$45.6M | -$51.0M |
| Income Tax | — | — | $0 |
| Net Income | -$27.9M | -$45.6M | -$51.0M |
| Diluted EPS | -$2.66 | -$1.45 | -$1.58 |
Sagimet Biosciences Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$12.9M | -$9.6M | -$10.7M | -$14.0M |
| Diluted EPS | -$0.40 | -$0.30 | -$0.33 | -$0.26 |
Sagimet Biosciences Balance Sheet
| FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|
| Cash & Equivalents | $75.1M | $75.8M | $35.0M |
| Current Assets | $96.6M | $152.8M | $116.4M |
| Total Assets | $96.7M | $160.3M | $116.5M |
| Current Liabilities | $5.7M | $4.5M | $5.1M |
| Total Liabilities | $5.7M | $4.5M | $5.1M |
| Shareholders' Equity | $91.1M | $155.8M | $111.4M |
Sagimet Biosciences Cash Flow Statement
| FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|
| Cash From Operations | -$23.8M | -$42.4M | -$45.6M |
| Cash From Investing | $12.6M | -$61.7M | $4.6M |
| Cash From Financing | $86.2M | $104.8M | $275,000 |
Figures from Sagimet Biosciences' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Sagimet Biosciences financials page for every line item.
Sagimet Biosciences Company Profile
| Ticker | SGMT |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Foster City, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001400118 |
Frequently Asked Questions
What was Sagimet Biosciences' revenue in fiscal 2025?
Sagimet Biosciences (SGMT) reported revenue of $0 for fiscal 2025.
What is Sagimet Biosciences' annual revenue history?
Sagimet Biosciences' annual revenue by fiscal year: 2023: $2.0M; 2024: $0; 2025: $0.
What was Sagimet Biosciences' net income in fiscal 2025?
Sagimet Biosciences reported net income of -$51.0M for fiscal 2025.
What was Sagimet Biosciences' earnings per share (EPS) in fiscal 2025?
Sagimet Biosciences' diluted EPS was -$1.58 for fiscal 2025 (adjusted for any later stock splits).
What was Sagimet Biosciences' revenue last quarter?
In its most recent reported quarter (2026 Q2), Sagimet Biosciences reported revenue of $0.
How many shares of Sagimet Biosciences are outstanding?
Sagimet Biosciences reported a weighted average of 53.1 million basic shares outstanding in 2026 Q2.
What is Sagimet Biosciences' market cap?
Based on its latest closing price, Sagimet Biosciences (SGMT) has a market capitalization of about $423.9M.
When does Sagimet Biosciences' fiscal year end?
Sagimet Biosciences' fiscal year end, as registered with the SEC, is December 31.
Where is Sagimet Biosciences headquartered?
Sagimet Biosciences lists its business address in Foster City, California in its SEC filings.